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Background: The emergence of antimicrobial resistance is of particular concern with
respect to urinary tract infections, since the majority of causative agents are Gram-
negative bacteria. Healthcare-associated urinary tract infections (HAUTIs) are
frequently associated with instrumentation of the urinary tract, specifically with
indwelling catheters.
Aim: To evaluate the current incidence, mortality, and length of hospital stay associated
with HAUTIs.
Methods: A non-concurrent cohort study design was used, conducted between January
1st, 2010 and June 30th, 2014. All patients admitted to one of the eight participating
Australian hospitals and who were hospitalized for more than two days were included. The
primary outcome measures were the incidence, mortality, and excess length of stay
associated with HAUTIs.
Findings: From 162,503 patient admissions, 1.73% [95% confidence interval (CI): 1.67
e1.80] of admitted patients acquired a HAUTI. Using a multi-state model, the expected
extra length of stay due to HAUTI was four days (95% CI: 3.1e5.0 days). Using a Cox
regression model, infection significantly reduced the rate of discharge (hazard ratio: 0.78;
95% CI: 0.73e0.83). Women were less likely to die (0.71; 0.66e0.75), whereas older pa-
tients were more likely to die (1.40; 1.38e1.43). Death was rarer in a tertiary referral
hospital compared to other hospitals, after adjusting for age and sex (0.74; 0.69e0.78).
Conclusion: This study is the first to explore the burden of HAUTIs in hospitals using
appropriate statistical methods in a developed country. Our study indicates that the
incidence of HAUTI, in addition to its associated extra length of stay in hospital, presents a
burden to the hospital system. With increasing incidence of UTI due to antimicrobial-Nursing and Health, Avondale College for Higher Education, Wahroonga, New South Wales, 2076,
edu.au (B.G. Mitchell).
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required.
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Healthcare-associated infections (HCAIs) including
healthcare-associated urinary tract infections (HAUTIs) are
frequently occurring and largely preventable infections
affecting the provision of healthcare globally. The point prev-
alence of HAUTIs isw1.4%, with HAUTIs responsible for 17% of
all HCAIs.1,2 The provision of evidence-based treatment is
essential in ensuring that healthcare professionals minimize
the incidence and attributed mortality of these opportunistic
infections. HAUTIs are frequently associated with instrumen-
tation of the urinary tract, specifically with indwelling cath-
eters.3e5 This represents an opportunity for relatively
inexpensive prevention strategies, such as minimizing catheter
use, appropriate insertion, careful maintenance and removal
of catheters at the earliest opportunity, coupled with ap-
proaches that are more systematic.5e10
The emergence of antimicrobial resistance is of particular
concern with respect to urinary tract infections (UTIs), since
the majority of causative agents are Gram-negative bacteria.11
This adds further value to endeavours that aim to understand
the burden of UTIs and interventions to reduce their incidence.
Our study aimed to evaluate the current incidence, mor-
tality, and length of stay associated with HAUTIs in a large
health district during a four-and-a-half-year period. We sought
to determine the proportion of patients that develop a
laboratory-diagnosed HAUTI, the extra length of hospital stay
in patients with HAUTI, and increased risk of inpatient mor-
tality associated with HAUTI.
Methods
Study design
A non-concurrent cohort study design was used.
Setting
The setting was a large health district in New South Wales,
Australia. The health district provides services to around
850,000 people (3.6% of Australia’s population) and covers a
geographical area of >130,000 km2. Eight hospitals within this
health district were included: one tertiary referral hospital,
two rural referral hospitals, and five district hospitals. The
combined total number of overnight beds at these hospitals
was 1250.
Participants
All patients admitted to one of the eight participating hos-
pitals between January 1st, 2010 and June 30th, 2014 and who
were hospitalized more than two days were included. The
sample timeframe was chosen by convenience consideration
and also to reflect the most recent data available.Definitions
HAUTI was considered present when patients had a positive
urine culture more than two days after admission, according to
the following criteria: positive for at least one species of
Enterobacteriaceae, >105/mL of urine, and no more than two
species of micro-organisms. This approach is consistent with
existing definitions and studies.12e15 All patients with a positive
urine culture not meeting this definition were excluded. When
a patient had more than one HAUTI during an admission, the
first HAUTI was included, all others excluded.
A healthcare-associated bacteraemia secondary to HAUTI was
defined as a positive blood culture occurring in a patient hospi-
talized>48 h,wherethe sourcewas theurinary tract, as indicated
by clinical findings and/or a positive urine culture with the same
isolate. This definition is considered further in the Discussion.
Multi-resistance was defined as an organism resistant to
three or more of amoxicillin þ clavulanate, ceftriaxone,
gentamicin, trimethoprim, or norfloxacin, using methods
described by the Clinical and Laboratory Standards Institute or
by the calibrated dichotomous sensitivity test method.
Data sources
Data were collected from two sources: the clinical coding
department and the microbiology department. The data sets
were merged using the unique district patient hospital number.
Data collected from the clinical coding department included
patient demographic data, admission and discharge dates,
date of death (inpatient mortality, if applicable) and Inter-
national Classification of Diseases (ICD-10AM) codes for each
patient admission. Microbiology data included cultured
organism(s), white cell count, and date of specimen collected.
Ethical considerations
Ethics approval for this project was provided by the Human
Research Ethics for the Health District and the Human Research
Ethics Committees at Avondale College of Higher Education.
Statistical analysis
A descriptive data analysis was performed using IBM SPSS
Version 20.0 (IBM, New York, NY, USA). Charlson comorbidity
index (CCI) was calculated using an algorithm developed by
Sundararajan et al.16 The CCI data were calculated to supply
basic comparisons between groups only. This variable was not
included in subsequent models, as the timing of comorbidities
within an admission period could not be determined due to
coding being completed on discharge. For example, we could
not determine whether a comorbidity occurred before or after
an infection. The comparisons of characteristics between those
who acquired HAUTI and those who did not were compared
using a chi-squared test or the ManneWhitney U-test for data
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tios were calculated using ManteleHaenszel methods.
Differences in length of stay between those with an infec-
tion and those without were calculated using a multi-state
model using the ‘etm’ package in R.17 Infection is a time-
dependent variable, and it is essential to use statistical
methods that account for this; otherwise, effects can be
severely biased.6,18,19 Our multi-state model uses four states:
susceptible, infected, discharged alive, and dead (Figure 1).
Patients become susceptible after admission and they may be
discharged, die, or they first become infected. If the time to
infection is not modelled, this leads to a time-dependent bias
that will overestimate the extra length of stay due to infec-
tion.20 The variance (and confidence intervals) in the extra
length of stay was estimated using 1000 bootstrap resamples.
To examine the risk of infection and death, we used the log
link in order to obtain the prevalence ratios for death, rather
than odds ratios (ORs) (logistic regression) which are prone to
time-dependent bias.21 We subsequently used a survival anal-
ysis using a Cox regression model with the day of admission as
the time variable to avoid a time-dependent bias.22 Results are
presented as hazard ratios and 95% confidence intervals (CIs).
Infection was modelled as a possible predictor of death or
discharge; we also examined the interaction between infection
and hospital to determine whether post-infection risks differ
by hospital. To understand how risk accumulates with time,
cumulative incidence functions were calculated.
Results
Overview
There were 162,503 eligible patient admissions from eight
participating hospitals. The principal referral hospital for the
health district accounted for 94,476 patient admissions (58%).
During this time, 2821 or 1.73% (95% CI: 1.67e1.80) of admitted
patients acquired a HAUTI. There was no statistically signifi-
cant difference in the annual incidence of patients acquiring a
HAUTI during the study period. Table I summarizes the char-
acteristics of the cohort, comparing those with a HAUTI to
those without. Females were significantly more likely to have
acquired an infection compared to males (unadjusted OR: 2.5;
95% CI: 2.3e2.7). Those who had an infection were also more
likely to die in the hospital than those without an infection
(unadjusted OR: 2.3; 95% CI: 1.9e2.7). There were significantlyHAUTI Dead
Susceptible Dischargedalive
Figure 1. Multi-state model used to determine length of stay.more patients who acquired a HAUTI at the tertiary referral
hospital than at a district hospital in the same health service,
at 1.9% vs 1.5% (P < 0.001). Seventy-eight percent of patients
with a HAUTI had a urine white cell count >50 cells/106/L.
Antimicrobial susceptibility data were analysed in patients who
had a HAUTI caused by one organism. These data are presented
in Table II.
Seven patients (0.22%) who had a HAUTI were subsequently
diagnosed with a healthcare-associated bacteraemia second-
ary to the HAUTI. In three instances, the causative organism for
the healthcare-associated bacteraemia was Escherichia coli.
All seven patients were discharged alive.
Length of stay
Using a multi-state model, the expected extra length of stay
due to HAUTI was four days (95% CI: 3.1e5.0) based on a
standard error of 0.48 days. The difference in the extra length
of stay remained relatively constant by day of infection
(Figure 2). The weight panel shows the frequency of infections
over time. The extra length of stay calculated for the tertiary
referral hospital in this study was 3.5 days [95% CI: 2.4e4.6;
standard error (SE): 0.55]. For all other hospitals combined, the
extra length of stay due to HAUTI was 5.0 days (95% CI: 3.4e6.6;
SE: 0.8).
Inpatient mortality
Table III presents the data using a Cox regression model
adjusting for age, sex, and admission to a tertiary hospital.
Women were more likely to acquire an infection and more
likely to be discharged. The elderly were less likely to be dis-
charged. There was a significantly reduced risk of discharge at
the tertiary referral hospital, which means generally longer
hospital stays. Infection also significantly reduced the rate of
discharge, which we saw previously with the increased length
of stay using a multi-state model.
An infection acquired in the tertiary referral hospital
significantly increased the relative hazard of discharge.
Therefore, compared with acquiring an infection in another
hospital, the extra length of stay is reduced in the tertiary
referral hospital. This result was also shown in the extra length
of stay estimates using a multi-state model (3.5 days in a ter-
tiary hospital versus 5 days in others). Women were less likely
to die, whereas older patients were more likely to die. Death
was rarer in the tertiary referral hospital compared to other
hospitals, after adjusting for age and sex, whereas acquiring an
infection reduced the risk of death.
Cumulative incidence functions are shown in Figure 3. Most
infections occurred within the first 50 days of admission (left
panel). The cumulative probability of discharge for an infected
patient was consistently below that for a non-infected patient
(central panel). The cumulative probability of death was
greater for an infected patient after around day 20 (right
panel). This increased risk was likely to be an indirect effect
resulting from the extra length of hospital stay.
Discussion
In all, 1.7% of patients who were hospitalized for more than
two days acquired a HAUTI. The elderly and females were at a
Table I
Characteristics of patients with and without a healthcare-associated urinary tract infection (HAUTI)
Characteristic HAUTI (N¼ 2821) No HAUTI (N¼ 159,682) Total (N¼ 162,503) P-value
Sex
Female 2095 (2.4%) 85,786 (97.6%) 87,881 <0.001
Male 726 (1.0%) 73,896 (99.0%) 74,622
Age (years)
Mean (SD) 73 (18.4) 51 (28.5) 52 (28.5)
Median 78 58 58 <0.001
Length of staya
Mean (SD) 33.3 (41.4) 8.7 (12.2) 9.1 (13.7)
Median 21 5 5 <0.001
Charlson comorbidity index
Mean (SD) 0.84 (1.4) 0.55 (1.1) 0.55 (1.2) <0.001
Median 0 0 0
Discharge outcome
Discharge alive 2660 (94.3%) 155,542 (97.4%) 158,202 (97.4%)
Inpatient mortality 161 (5.7%) 4140 (2.6%) 4301 (2.6%) <0.001
Hospital
Tertiary referral hospital (N¼ 1) 1819 (1.9%) 92,657 (98.1%) 94,476 <0.001
District hospitals (N¼ 7) 1002 (1.5%) 67,025 (98.5%) 68,027
Infection details
Mean days to infection 13.7 (18.1) e
Median days to infection 8 e
Causative organisms 3126
Escherichia sp. 1735 (55.5%)
Klebsiella sp. 401 (12.8%)
Proteus sp. 341 (10.9%)
Citrobacter sp. 271 (8.7%)
Enterobacter sp. 219 (7.0%)
Morganella sp. 80 (2.6%)
Serratia sp. 57 (1.8%)
Providencia sp. 10 (0.3%)
Pantoea sp. 6 (0.2%)
Salmonella sp. 3 (0.1%)
Raoutella sp. 2 (0.1%)
Hafnia sp. 1 (<0.1%)
a Provided for background information only. This analysis suffers from length bias.
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HAUTI, the average extra length of stay in hospital is four days.
The incidence of HAUTIs, in addition to the extra length of stay,
suggests that HAUTIs place a significant burden on health ser-
vices. The use of appropriate statistical methods to estimate
length of stay due to HAUTIs has been rarely reported in the
literature and this study is the first to publish results using a
multi-state model from patients in a developed country. As
such, our study provides reliable and valuable information for
clinicians, infection control professionals, health administra-
tors and policy-makers regarding why HAUTI prevention mea-
sures need to be further strengthened.
The incidence of 1.7% of patients acquiring a HAUTI is
consistent with other literature, but lower than a multi-
centred French study that reported an incidence of
4.8%.1,3,23,24 In the USA, a recent multi-site point prevalence
study involving 183 hospitals identified the point prevalence of
all HCAIs as 4.0%, with 14.4% of these having a HAUTI.25 An
alarming finding from that study was that 23.6% of all patients
on the survey day had a urinary catheter in place.25 As HAUTIs
are frequently associated with urinary catheters, this favoursindwelling catheter interventions, such as the prevention of
catheter insertion in the first instance and early catheter
removal.26 This point is of greater consequence, as the ma-
jority of HAUTIs occur after catheter insertion, which is often
unnecessary, as well as due to clinicians being unaware of their
existence.27e30 In our study, we were unable to obtain data on
catheter use and the proportion of HAUTIs that were catheter-
related. However, we have reported contemporary estimates
of the incidence of HAUTIs in Australian settings in previous
work.1
Studies have documented the extra length of stay due to
HAUTIs.31,32 However, the statistical analysis undertaken did
not account for time-dependent bias, and therefore the results
are likely to overestimate the impact.20,33,34 The only study we
identified that estimated the extra length of stay due to HAUTIs
that accounts for time-dependent bias was conducted on data
from 10 developing countries.35 On average, a UTI infection led
to 1.59 extra days (95% CI: 0.58e2.59) in the intensive care
unit. The extra length of stay was longest in Turkey (mean: 5.88
days).35 Our study, conducted in a developed country, identi-
fied a much higher length of stay due to HAUTIs. If the extra
Table II
Antimicrobial susceptibility for urine isolates in patients with a healthcare-associated urinary tract infection (HAUTI)
Organism group No. of
strains
% total Percent susceptible Multi-resistanta
Ampicillin Cefazolin/cephalexin Nitrofurantoin Amoxicillinþ clavulanate Ceftriaxone Gentamicin Trimethoprim Norfloxacin
CLSI
All isolates 1191 100 35% 54% 73% 68% 96% 94% 78% 97% 5%
Escherichia coli 751 63% 44% 63% 97% 75% 98% 96% 79% 96% 3%
Klebsiella sp. 147 12% 0 57% 51% 86% 95% 93% 86% 98% 6%
Proteus mirabilis 114 10 75% 59% 2% 87% 99% 99% 65% 99% 1%
Enterobacter sp. 66 6% 2% 2% 27% 3% 73% 73% 62% 95% 30
Citrobacter sp. 48 4% 0 21% 88% 23% 83% 81% 85% 100 15%
Morganella sp. 29 2% 0 0 3% 0 97% 97% 62% 100 3%
Serratia sp. 30 3% 0 0 0 0 100 100 93% 100 0
Other sp.b 6 1% 0 33% 50 50 100 100 83% 100 0
CDS
All isolates 676 100 53% 87% 80 88% N/T 97% 89% 97% 2%
Escherichia coli 441 37% 66% 97% 98% 97% 98% 88% 98% 1%
Klebsiella sp. 77 6% 8% 88% 59% 92% 95% 89% 96% 4%
Proteus mirabilis 65 5% 83% 97% 12% 99% 100 94% 100 0
Enterobacter sp. 52 4% 12% 31% 36% 29% 92% 92% 96% 6%
Citrobacter sp. 24 2% 8% 48% 73% 46% 88% 88% 85% 13%
Morganella sp. 8 1% 13% 0 20 0 100 100 100 0
Serratia sp. 5 0 0 60 80 60 100 80 100 0
Providentia sp. 4 0 0 0 0 0 100 100 100 0
N/T, not tested.
CLSI, Clinical and Laboratory Standards Institute, http://clsi.org/.
Calibrated Dichotomous Sensitivity (CDS) Test Method, Sydney, Australia: an Australian antimicrobial testing standard, http://web.med.unsw.edu.au/cdstest/GTF_CDS_site/
WebPages/HomeLevel/CDSoverview.htm.
Antimicrobial susceptibility data were analysed in patients who had a HAUTI caused by one organism. During the study period, four hospitals used a laboratory using CLSI and four
hospitals used CDS. No changes in methods were undertaken during the study period.
a Resistant to three or more of amoxicillinþ clavulanate, ceftriaxone, gentamicin, trimethoprim, or norfloxacin.
b Raoutella and Providentia species.
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to the rate identified in our study, the burden HAUTIs place on
healthcare systems internationally would be considerable.
Further, there are additional costs, such as diagnostic and
medical costs, associated with catheter-associated UTIs, one
widespread type of HAUTI.36
Our data suggest that 1.73% of patients admitted to hospital
acquire a HAUTI. Assuming there are 5.5 million admissions to
public hospitals each year in Australia, w95,150 patientsTable III
Risk of HAUTI, discharge, and death using a Cox regression model
Outcome Predictor HR 95% CI P-value
HAUTI Sex (female) 2.74 2.57e3.04 <0.001
HAUTI Age (10-year increase) 1.31 1.28e1.33 <0.001
HAUTI Tertiary hospital 1.26 1.16e1.37 <0.001
Discharge Sex (female) 1.12 1.11e1.13 <0.001
Discharge Age (10-year increase) 0.91 0.91e0.92 <0.001
Discharge Tertiary hospital 0.80 0.79e0.80 <0.001
Discharge HAUTI (yes vs no) 0.78 0.73e0.83 <0.001
Discharge Tertiary hospital and
HAUTI
1.23 1.14e1.32 <0.001
Dead Sex (female) 0.71 0.67e0.75 <0.001
Dead Age (10-year increase) 1.40 1.38e1.43 <0.001
Dead Tertiary hospital 0.74 0.69e0.78 <0.001
Dead HAUTI (yes vs no) 0.77 0.60e0.98 0.034
Dead Tertiary hospital and
HAUTI
1.08 0.78e1.48 0.650
HAUTI, healthcare-associated urinary tract infection; HR, hazard
ratio; CI, confidence interval.admitted would acquire a HAUTI each year in Australia
(assuming that our data were nationally representative).37 This
equates tow380,600 extra public hospital bed-days used each
year in Australia, purely because of patients acquiring a HAUTI
in hospital. A 10% reduction in the incidence of HAUTI could
free up w38,600 bed-days.
We identified that the risk of acquiring a HAUTI was higher in
a tertiary referral hospital compared to district hospitals.
Perhaps this reflects more complex and older patients being
admitted to this type of hospital. However, deaths were rarer
in the tertiary referral hospital compared to other hospitals
after adjusting for age and sex. Conversely, acquiring an
infection reduced the risk of death, perhaps reflecting the
ability of a tertiary referral hospital to successfully treat and
manage those with a HAUTI. We identified differences in
mortality between those with a HAUTI and those without,
consistent with other studies.32,35,38 However, after adjusting
for other factors, we were unable to identify any difference in
mortality between hospitals, a finding consistent with Rosen-
thal et al.35
There are limitations to our study. Our use of a laboratory-
diagnosed definition of a HAUTI would contribute to an ascer-
tainment bias. This may result in an underestimation of the
incidence of HAUTIs, as uncomplicated UTIs may be diagnosed
and treated by clinicians without sending a laboratory sample
for culture. Furthermore, positive cultures with Gram-positive
or fungal pathogens or with low counts of Enterobacteriaceae
were excluded. Conversely, complicated or recurring UTIs are
potentially more likely to have a urine sample sent for analysis.
Also, for various reasons, urine cultures that exhibit bacteriuria
may be submitted from minimally symptomatic patients who
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address this concern, we reviewed the medical notes of a
random sample of 318 HAUTI patients. The sample number of
318 was based on a 5% margin of error, with a 50% distribution
of patients who had an electronic medical record. The vast
majority of these patients (83%; 95% CI: 74e94%) had signs or
symptoms of UTI (based on definitions from the National
Healthcare Safety Network, Centers for Disease Control and
Prevention, Atlanta, GA, USA) or a medical diagnosis of UTI
explicitly documented in their notes.12 Of the remainder (54
patients), 50% (N ¼ 27) had catheter, making diagnosis more
challenging. None the less, 13 of the 27 patients had docu-
mented evidence of a change in urine appearance coinciding
with the specimen collection date. We therefore believe the
definition applied in our study was robust and suitable for the
outcome measures observed. The definition we used is
consistent with one approach described in the literature.39,40
We were also unable to ascertain the proportion of HAUTIs
that were catheter-associated or catheter utilization rates.
Such an analysis was beyond the available resources due to the
sample size of the study and, as catheter-associated UTIs were
not an outcome measure, such data are not relevant.
Our study indicates that the incidence of HAUTI, alongside
its associated extra length of stay in hospital, presents a
burden to the Australian hospital system. These findings,
coupled with increasing antimicrobial resistance and point
prevalence studies undertaken in several Australia hospitals,
suggest that it is time to consider systematic interventions to
reduce the incidence and the potential for a form of national
HAUTI surveillance.1Acknowledgements
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